Sarepta Therapeutics Inc (SRPT) Option Bulls Bet On New Highs

Sarepta Therapeutics Inc (NASDAQ:SRPT) call options have been popular, but there may be an ulterior motive for these traders

Dec 18, 2015 at 2:24 PM
facebook twitter linkedin


Call buyers have been piling into Sarepta Therapeutics Inc's (NASDAQ:SRPT) options pits recently. Looking at data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the equity boasts a 10-day call/put volume ratio of 15.16. This reading outranks 78% of all others from the past year, meaning there's been a greater-than-usual appetite for long calls over long puts recently. 

Echoing this preference for calls is SRPT's Schaeffer's put/call open interest ratio (SOIR). At 0.44, it shows that call open interest more than doubles put open interest, among options that expire within the next three months. 

This trend is continuing today. Call volume is accelerated, and the most popular option by a long shot is the May 50 call. It's likely traders are buying to open the deep out-of-the-money call, betting on SRPT to topple the half-century mark by May expiration -- for the first time since October 2013. 

Widening the sentiment scope, though, shows these call players may actually be short sellers looking for insurance. Short interest increased by over 12% during the past two reporting periods, and now accounts for more than one-fourth of SRPT's float. 

Elsewhere, analysts are mostly bullish on the drugmaker. Twelve brokerage firms are covering the stock, eight of which say it's a "buy" or better, with none calling it a "sell." Additionally, SRPT's consensus 12-month price target of $46.75 is located in two-year-high territory. 

The shares are enjoying a 161% lead in 2015, recently consolidating gains from a late-November bull gap. Today, traders are responding to news that rival drug company BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) muscular dystrophy drug still hasn't been approved by the Food and Drug Administration (FDA). As a result, Sarepta Therapeutics Inc (NASDAQ:SRPT) has gained 5.6% to hit $37.82.
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners